Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT1308 + Chemo in dMMR Endometrial Cancer
NCT06321068Phase 3Terminated
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Apr 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of BAT1308 in endometrial cancer (EC), sponsored by Bio-Thera Solutions, Ltd.. Started Apr 2024; status: terminated.
02
Drugs
BAT1308
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06321068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06321068.